Global Blood Therapeutics Stock Forecast, Price & News

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

Is Global Blood Therapeutics a buy right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics or view top-rated stocks.

How has Global Blood Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GBT stock has decreased by 46.0% and is now trading at $29.62.
View which stocks have been most impacted by COVID-19.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Global Blood Therapeutics.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($1.13) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to analysts' expectations of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 79.04% and a negative net margin of 154.11%. The company's revenue for the quarter was up 41.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.97) earnings per share.
View Global Blood Therapeutics' earnings history.

What price target have analysts set for GBT?

15 brokerages have issued twelve-month target prices for Global Blood Therapeutics' shares. Their forecasts range from $36.00 to $124.00. On average, they anticipate Global Blood Therapeutics' share price to reach $63.31 in the next twelve months. This suggests a possible upside of 113.7% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:

• Ted W. Love, President, Chief Executive Officer & Director
• Nazila Habibizad, Senior Vice President-Operations
• Jeffrey S. Farrow, Chief Financial & Accounting Officer
• Kim Smith-Whitley, Executive VP, Head-Research & Development
• Jung E. Choi, Chief Business & Strategy Officer

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Global Blood Therapeutics' key competitors?

Some companies that are related to Global Blood Therapeutics include Jazz Pharmaceuticals (JAZZ), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Sarepta Therapeutics (SRPT), Grifols (GRFS), Legend Biotech (LEGN), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Zai Lab (ZLAB), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Blueprint Medicines (BPMC), HUTCHMED (HCM), Perrigo (PRGO) and Cerevel Therapeutics (CERE).
View all of GBT's competitors.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.73%), BlackRock Inc. (9.25%), Perceptive Advisors LLC (6.84%), Casdin Capital LLC (2.99%), Franklin Resources Inc. (2.62%) and Capital World Investors (2.26%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics.

Which major investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Franklin Resources Inc., Morgan Stanley, Frontier Capital Management Co. LLC, Dimensional Fund Advisors LP, Deutsche Bank AG, First Midwest Bank Trust Division, and Geode Capital Management LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Philip A Pizzo, and Scott W Morrison.
View insider buying and selling activity for Global Blood Therapeutics or view top insider-selling stocks.

Which major investors are buying Global Blood Therapeutics stock?

GBT stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Polar Capital Holdings Plc, Perceptive Advisors LLC, Candriam Luxembourg S.C.A., Connor Clark & Lunn Investment Management Ltd., Goldman Sachs Group Inc., Janus Henderson Group PLC, and Natixis. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eric Fink, and Willie L Jr Brown.
View insider buying and selling activity for Global Blood Therapeutics or or view top insider-buying stocks.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $29.62.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics has a market capitalization of $1.91 billion and generates $123.80 million in revenue each year. The company earns $-247.55 million in net income (profit) each year or ($4.46) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 389 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

Where are Global Blood Therapeutics' headquarters?

Global Blood Therapeutics is headquartered at 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 741-7700 or via email at [email protected].